FDA Approves Atezolizumab Regimen for Frontline Small Cell Lung Cancer

March 19, 2019 – The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The approval is based on findings from the phase III IMpower133 study, which demonstrated that the addition of atezolizumab to carboplatin and etoposide led to a significant improvement in overall survival (OS) in patients with ES-SCLC. “Atezolizumab is … (leggi tutto)